ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Court Orders NIH To Retract Electronic Annotations On Fisher Publications

March 24, 1995

In Brief: Mathews Could Help In Fighting OMB Obstruction Of Cancer Program; Easily Wins Senate Approval

August 1, 1975

Angiogenesis Inhibitor In Phase III Trials For Metastatic Colorectal Cancer

September 26, 2003

Guest Editorial: caBIG Has Another Fundamental Problem: It Relies On “Incoherent” Messaging Standard

April 22, 2011

40 Years Later: Doctor and Patient Reflect on the Cure

October 24, 2014

NIH Revitalization Act Authorizes $3 Billion For NCI In FY97

July 5, 1996